#United States #New Orleans #Clinical Trials #Ochsner Health #Paradigm Health

Expanding Clinical Trial Access with AI

In a groundbreaking partnership, Ochsner Health and Paradigm Health have joined forces to enhance access to clinical trials across the Gulf South region. This collaboration is not just about improving efficiency; it's about transforming the way patients engage with healthcare, particularly in clinical research. The integration of Paradigm Health's AI-driven recruitment platform within Ochsner's extensive healthcare network promises to open new doors for patients at a time when clinical trials can offer critical treatment options.

Improving Patient Recruitment

Ochsner Health, the leading nonprofit academic healthcare system in the Gulf South, has embarked on a significant mission to expand its clinical trial participation rates. Utilizing Paradigm Health's innovative AI technology, which meticulously reviews patient data across 47 hospitals and 370 health centers, Ochsner has achieved a remarkable 41% increase in screening capacity for potential trial candidates. This increase is vital for connecting eligible patients with research opportunities, fundamentally changing the landscape of clinical trials in the region.

The Role of AI in Identifying Patients

Clinical trials are essential for developing new treatments and ensuring patients have access to potentially life-saving therapies. However, the traditional methods of patient recruitment often leave many eligible individuals overlooked. Paradigm Health's AI platform addresses this issue by continuously assessing patient eligibility against clinical trial criteria, enabling a proactive approach to recruitment. This means Ochsner's medical staff can identify patients who may not yet qualify for a trial but could be viable candidates as they progress through their treatment, thus maximizing their chances of being included in research.

Notable Results from the Partnership

The outcomes from this partnership have been impressive:

• - A 3.6x increase in patients identified for future trial eligibility indicates the effectiveness of real-time data assessments in clinical settings.
• - There is a 75% reduction in manual efforts involved in identifying and assessing potential trial participants. This efficiency frees up valuable time for clinical research coordinators, allowing them to focus more on patient interactions rather than paperwork.

Dr. Nneka Ifejika, the chief scientific officer at Ochsner Health, emphasizes the importance of this initiative: "By adopting a more holistic view of our patients' eligibility for trials, we are not limited to individual clinic encounters, but are capable of tracking patient eligibility throughout their treatment journey."

A Revolutionary Shift in Clinical Research

Wendy Chriss, Ochsner's director of clinical research, echoed similar sentiments about the transformative nature of this partnership. The automation of complex manual processes aligns with their goal to make clinical trials more inclusive and accessible, helping to dismantle barriers that have historically excluded many patients from participating in vital research.

Kent Thoelke, founder and CEO of Paradigm Health, also noted that their AI-enabled infrastructure is key to addressing the shortcomings of traditional clinical trial models. By embedding this intelligent system into healthcare providers' existing workflows, they aim to rapidly improve trial access and mitigate coordinator burnout, ultimately leading to faster delivery of treatments to patients.

Conclusion

Ochsner Health's collaboration with Paradigm Health marks a pivotal moment in the clinical research landscape. The integration of cutting-edge technology to address recruitment challenges positions Ochsner as a leader in patient care and research accessibility in the Gulf South. As they continue to implement this AI-driven model, it is anticipated that even more patients will have the opportunity to participate in clinical trials, paving the way for advancements in treatment and healthcare outcomes across the region.